Transthyretin Amyloidosis

ATTR amyloidosis is far more common than its diagnosed population suggests. The US carries an estimated 100,000-150,000 ATTR cardiomyopathy (ATTR-CM) patients, most still undiagnosed, and a patient-flow lens counts over 500,000 people aged 70+ with HFpEF who likely harbour undiagnosed wild-type disease (ATTRwt, roughly 80% of ATTR-CM). Hereditary ATTRv, with the Val122Ile variant most common in the US, adds 100,000+ carriers. The UK estimates 20,000-40,000 ATTRwt-CM and the GCC 15,000-25,000. The gap between estimated and diagnosed prevalence, not treatment access, defines the disease.

ATTR splits into two phenotypes with two diagnostic doors. The cardiac form, ATTR-CM, is now confirmed non-invasively by technetium-pyrophosphate (Tc-PYP) scintigraphy once echocardiographic red flags such as increased wall thickness and apical-sparing strain trigger the scan and a monoclonal protein is excluded; genetic testing then separates ATTRv from ATTRwt. The neuropathic form, ATTR-PN, still carries a 4-5 year misdiagnosis delay. Because symptoms mimic ordinary heart failure or peripheral neuropathy, case-finding, not therapy, is the rate-limiting step of the funnel.

Approved therapy spans two mechanisms and two indications. For ATTR-CM, oral TTR stabilisers tafamidis (Vyndaqel/Vyndamax, Pfizer) and acoramidis (Attruby, BridgeBio, approved November 2024) compete, and vutrisiran (Amvuttra, Alnylam) gained an ATTR-CM indication in March 2025. For ATTR-PN, RNA silencers patisiran, vutrisiran and inotersen are used. Tafamidis anchored the stabiliser class with a 29.5% relative reduction in all-cause mortality in its pivotal ATTR-ACT trial. The exact recommended set and regulatory routing differ by market.

You build it bottom-up as a funnel, never top-down from prevalence. Start from the elderly HFpEF pool of 500,000+ US patients aged 70+ in the ATTRwt case, then apply a scintigraphy-suspicion rate, a Tc-PYP scan rate, and a confirmation yield to reach the roughly 70,000-100,000 diagnosed and treated today. The gap between findable and found is the forecast, and cardiology referral rate is the lever that moves it, so you run sensitivity on scan penetration rather than on price. Each market re-anchors the funnel: the UK's 20,000-40,000 estimate yields a 15,000-36,000 undiagnosed gap, and the GCC's broad 15,000-25,000 burden collapses to under 1,000 confirmed. In rare disease the identification funnel is the strategy, not the label.

Tc-PYP scintigraphy replaced biopsy as the confirmatory test, so scan-centre capacity, not disease biology, now sets how fast the funnel fills. You treat diagnostic infrastructure as the rate-limiting variable and model diagnosed prevalence as a function of centre count and throughput. The UK is the cleanest case: after the 2021 NHS Tc-PYP pathway, annual ATTR-CM diagnoses rose from under 500 to 2,000-5,000 across roughly 30 centres. The GCC shows the opposite constraint, with fewer than 8 scintigraphy centres across six states capping uptake regardless of price or formulary status. So the forecast runs a scintigraphy-penetration sensitivity on centres added per year and referrals per centre, because every incremental scanner, not every rebate, converts a findable patient into a treated one.

ATTR is really two commercial markets wearing one name. The cardiac phenotype, ATTR-CM, sits in cardiology and HFpEF clinics and is dominated by wild-type disease (ATTRwt, roughly 80%); the neuropathic phenotype, ATTR-PN, sits in neurology, is hereditary (ATTRv), and carries its own 4-5 year misdiagnosis delay. They run on different referral pathways, diagnostic tests, KOLs, and approved agents, so you forecast them as separate funnels and never blend prevalence. Hereditary subpopulations then get their own layer, from Val122Ile carriers in the US to the Ala97Ser and Thr60Ala variants in the GCC and UK registries, because genetics reshapes both the addressable pool and the case-finding route. Segment first, size second: a single ATTR number is a forecasting error, not a market.

With no head-to-head trial between stabilisers and silencers, positioning rests on indirect comparison and mechanism narrative rather than a superiority claim. You map the field as two mechanism classes, oral TTR stabilisers (tafamidis, acoramidis) against RNA silencers (patisiran, vutrisiran), then build the value case market by market. In the US the argument is priced against ICER's fair-value gap, because tafamidis lists near $268,000 yet sits outside IRA Medicare negotiation under the orphan-drug exclusion while two-stabiliser rebating already runs net prices well below list. In the UK the comparator is an invisible cost-minimisation floor set by NICE, which recommends both stabilisers and directs clinicians to the cheaper one, so a third entrant must beat a confidential net price, not a QALY threshold. In the GCC the value case is diagnostic access, not price. Geography rewrites the argument each time.

Every answer here rests on one connected model. The patient-flow funnel triangulates true versus diagnosed prevalence across ATTRwt-CM, ATTRv and ATTR-PN; the competitive read positions the approved agents across two mechanisms with no head-to-head; the payer and HTA layer maps the divergent US, UK and GCC value cases; KOL mapping tiers the amyloidosis-centre network, the National Amyloidosis Centre in the UK and KFSH&RC in the GCC, that gates diagnosis; and the pricing model reconciles WAC, ICER fair value and rebate-driven net price. AXLRx builds this stack for ATTR across the US, UK and GCC, each figure verified to primary sources, because in rare disease the identification funnel is the strategy, not the label.